Market Highlights

The global DNA vaccines market was estimated at US$ 433 million in 2021 and is expected to grow at a CAGR of 6.18% during 2022-2028 to reach US$ ~654 million in 2028.

DNA Vaccines Market CAGR

2022-2028

CAGR OF

6.18%

DNA Vaccines Market

The DNA vaccine industry is rapidly moving from a rational design approach to one that is based primarily on empirical data. Recent developments in immunobiology, DNA synthesis, and molecular biology enable rational design approaches. These techniques allow for highly targeted vaccinations against specific epitopes. As a consequence, more vaccines are developed to cover a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. The discovery and development of high-value vaccines for novel applications is made possible by these new technologies, which present pharmaceutical companies with a substantial new market.

A DNA vaccine is a small circular DNA plasmid that is directed by a promoter to encode one or more protein antigens to mount a specific defense against an illness. The unfavorable aspects of conventional vaccinations were specifically addressed by the development of DNA vaccines, the third generation of vaccines. The population is growing more vulnerable to infectious diseases, and the number of infections resistant to antibiotics has increased. This has made the development of effective and reasonably priced long-lasting vaccines necessary.

The main factors propelling the DNA vaccines market are the rise in the prevalence of infectious diseases and cancer in both humans and animals, as well as the growing demand for these vaccines because of their advantages over other immunization methods, such as lower risk of infection, ease of transportation, and stability at room temperature. The increase in antibiotic-resistant bacteria has also increased demand for effective and reasonably priced vaccinations, such as DNA vaccines, which offer long-lasting protection. 
But the lack of immunogenicity associated with DNA vaccines might make market growth difficult. Additionally, it is expected that the lack of complete knowledge regarding the effects of DNA vaccines on humans will limit the DNA vaccines market's growth. However, a number of factors are expected to offer profitable growth opportunities for businesses in the DNA vaccines market. These include the development of novel vaccines using DNA technology and the enormous growth potential in developing and underdeveloped countries.

DNA Vaccines Market

By Region

The Market will Grow

At the CAGR of:

6.18%

The Forecast Market

Size for 2028 in USD:

$650M

The vaccine industry is rapidly moving from a rational design approach to one that is based primarily on empirical data. Recent developments in immunobiology, DNA synthesis, and molecular biology enable rational design approaches. These techniques allow for highly targeted vaccinations against specific epitopes. As a consequence, more vaccines are developed to cover a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. The discovery and development of high-value vaccines for novel applications is made possible by these new technologies, which present pharmaceutical companies with a substantial new market.
Over the past few years, there has been a significant increase in the need for vaccines due to the widespread prevalence of diseases. DNA vaccines Market participants have opportunities because of these vaccinations' exceptional efficacy in preventing infectious diseases.

DNA vaccinations may facilitate the eradication of illnesses such as HIV, hepatitis, cancer, and others. Furthermore, vaccinations are typically recommended for travelers due to their higher than average risk of contracting numerous diseases. It is advised that travelers receive vaccinations against diseases like cholera, hepatitis, meningitis, Japanese encephalitis, typhoid fever, yellow fever, rabies, polio, and tickborne encephalitis. A few well-known tourist destinations have seen high rates of the aforementioned diseases, which has raised demand for DNA vaccines globally.
 

It is also recommended to have regular vaccinations against diseases such as human papilloma virus, hepatitis A, hepatitis B, haemophilus influenza type B, cholera, dengue, tetanus, tetanus, and pertussis (DTP). An increase in the incidence of pneumococcal and influenza infections also drives up demand for DNA vaccines. Moreover, DNA vaccines have a wide range of uses and provide humoral and cell-mediated protection. The three primary clinical goals of DNA vaccines are influenza, papillomavirus, and HIV. The World Health Organization lists cervical cancer, which is caused by HPV, as the third most common cause of death globally. Two HPV vaccinations that are meant to prevent the virus were developed in 2006 and 2009, respectively, by Merck and GlaxoSmithKline, respectively. 
Recent years have seen a number of directives and investments in the sector that should expand the DNA vaccines market as a whole. Among them are the following: • DNA vaccines are aimed at a range of traditional pharmaceutical markets, such as allergies, cancer, and infectious diseases. The larger vaccination industry proved its capacity to create products with innovative uses and potential blockbuster sales with the launch of Merck's Gardasil. DNA vaccines are prepared to take advantage of this new business approach and open up a sizable DNA vaccines market.
• New bio- and nanotechnologies are driving the development of DNA vaccines. For DNA vaccines to reach their full potential, new vaccine formats like DNA prime-adenovector boost, innovative molecular adjuvant technologies, and emerging delivery techniques like electroporation (EP) are especially important. People now have the resources they need to work more productively thanks to these technologies.
The development of DNA vaccines has already made great strides. There are nearly 100 ongoing human clinical trials for a variety of disorders, and there is a sizable pipeline of preclinical initiatives. Applications for research instruments and animal health comprise a tiny but crucial market niche these days.
 

DNA Vaccines Market

By Product Type

XX%

Oncept

West Nile-Innovator

Apex-IHN

430

Total Market Size

USD (Million), 2022

6.18%

CAGR

2022 - 2028

Market Segments Analysis

Based on product type, type, and end user, the DNA Vaccines market is segmented. The DNA vaccines market is further divided into Oncept, West Nile-Innovator, and Apex-IHN based on the type of product.
The DNA vaccines market has been segmented into two categories based on type: prophylactic and therapeutic vaccines.

The DNA vaccines market is divided into hospitals, clinics, and other end-user segments.
Geographically speaking, the DNA vaccines market is divided into regions such as North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

DNA Vaccines Market

By Type

Therapeutic Vaccine

Prophylactic Vaccine

The Market will Grow

At the CAGR of:

6.18%

The Forecast Market

Size for 2028 in USD:

$650M

Key Players

DNA vaccines are a very competitive market. The growth of the businesses is directly impacted by the status of the economy and government support. These companies differentiate their DNA vaccines driver in the industry based on the quality of their product and its market penetration in both target and growing markets. Furthermore, the dynamics of competition have been significantly impacted by recent significant mergers and acquisitions in the industry. 

For example:
• Zydus Cadila Emergency Use Authorization (EUA) for ZyCoV-D, the first DNA-based COVID-19 vaccine made fully in India and authorized for use in humans, including children and adults 12 years of age and older, was granted in August 2021 by the Drug Controller General of India (DCGI). BIRAC is in charge of Mission COVID Suraksha, which was developed in partnership with the Indian government's Department of Biotechnology.
• Eli Lilly and GlaxoSmithKline, along with biotech partner Vir, inked a contract in January 2021 for the testing of their COVID-19 antibody bamlanivimab 700 mg, which was cleared for use in an emergency, in conjunction with GSK/investigational Vir's VIR-7831 (also known as GSK4182136) 500 mg treatment.

The overall competitive landscape has been affected due to these strategic activities. The following are the major players in the DNA vaccines market:
• BOEHRINGER INGELHEIM GmbH (Merial)
• ELI-LILLY (Novartis Animal Health)
• GeneOne Life Science
• Genexine, Inc.
• GEOVAX LABS, INC
• Inovio Pharmaceuticals (VGX Animal Health)
• Takara Holdings (Takara Bio)
• VIATRIS INC. (Rottapharm Biotech)
• ZOETIS INC. (Fort dodge Animal Health)
• Zydus Cadila

DNA Vaccines Market Scope: